Modafinil
Wakefulness-Promoting Agent for Narcolepsy and Sleep Disorders
Quick Facts About Modafinil
Key Takeaways About Modafinil
- Targeted wakefulness promotion: Modafinil treats excessive daytime sleepiness in narcolepsy, obstructive sleep apnea, and shift work sleep disorder without the broad stimulant effects of amphetamines
- Hormonal contraceptive warning: Modafinil reduces the effectiveness of hormonal contraceptives (pill, patch, ring) – use alternative contraception during treatment and for 2 months after stopping
- Serious skin reactions: Discontinue immediately and seek medical attention if you develop a rash, as rare cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported
- Not a substitute for sleep: Modafinil does not replace adequate sleep and should be used alongside good sleep hygiene and, for obstructive sleep apnea, continuous positive airway pressure (CPAP) therapy
- Lower abuse potential than amphetamines: Classified as Schedule IV (not Schedule II like amphetamines), but psychological dependence can still occur – take only as prescribed
What Is Modafinil and What Is It Used For?
Modafinil is a wakefulness-promoting agent (eugeroic) prescribed to treat excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea (as an adjunct to CPAP), and shift work sleep disorder. It works primarily by inhibiting dopamine reuptake and activating orexin/hypocretin neurons in the brain.
Modafinil belongs to a unique class of medications known as eugeroics, meaning "good arousal." Unlike traditional psychostimulants such as amphetamines or methylphenidate, which produce broad central nervous system stimulation, modafinil promotes wakefulness through more selective mechanisms. It was first approved by the U.S. Food and Drug Administration (FDA) in 1998 for the treatment of narcolepsy and has since become one of the most widely prescribed medications for excessive sleepiness.
In patients with narcolepsy, modafinil helps counteract the overwhelming and uncontrollable urge to sleep during the day. Narcolepsy is a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles normally, often due to a deficiency of orexin (hypocretin) neurons. While modafinil does not cure narcolepsy, it significantly improves daytime alertness and functional capacity, allowing patients to lead more normal lives.
For patients with obstructive sleep apnea (OSA), modafinil is used as an adjunctive treatment to address residual excessive sleepiness that persists despite adequate use of continuous positive airway pressure (CPAP) therapy. It is important to understand that modafinil does not treat the underlying airway obstruction in OSA and should never be used as a replacement for CPAP or other primary treatments.
In shift work sleep disorder (SWSD), modafinil is taken approximately one hour before the start of a work shift to promote wakefulness in individuals who work non-traditional hours (such as night shifts or rotating shifts) and experience clinically significant sleepiness that affects their ability to function safely.
Modafinil is sometimes used off-label as a cognitive enhancer or "smart drug," but this use is not approved by regulatory agencies. The American Academy of Sleep Medicine (AASM) recommends modafinil only for its approved indications. Using modafinil without a prescription is illegal in many countries and carries health risks, including serious skin reactions and cardiovascular effects.
What Should You Know Before Taking Modafinil?
Before starting modafinil, inform your doctor about all medical conditions, especially a history of skin rashes with medications, heart problems, psychiatric disorders, liver or kidney disease, and any history of substance abuse. Modafinil is contraindicated in patients with known hypersensitivity to modafinil or armodafinil.
Contraindications
You should not take modafinil if any of the following apply to you:
- Allergy to modafinil or armodafinil – if you have previously experienced a hypersensitivity reaction, including rash, hives, or difficulty breathing, with either medication
- Uncontrolled moderate-to-severe hypertension – modafinil may increase blood pressure and heart rate
- Clinically significant cardiac arrhythmias – modafinil should not be used in patients with certain heart rhythm disorders
- Pregnancy – modafinil may cause foetal harm; animal studies have shown developmental toxicity and there is insufficient human data to confirm safety
Warnings and Precautions
Talk to your doctor or pharmacist before taking modafinil if you have or have had any of the following:
- History of psychiatric disorders – modafinil can trigger or worsen anxiety, mania, psychosis, depression, and suicidal ideation, particularly in patients with a pre-existing psychiatric history
- Cardiovascular disease – including left ventricular hypertrophy, mitral valve prolapse, recent myocardial infarction, or unstable angina. Modafinil can increase heart rate and blood pressure
- History of drug or alcohol abuse – although the abuse potential is lower than amphetamines, modafinil acts on dopamine pathways and may be misused
- Liver impairment – modafinil is extensively metabolised by the liver, and the dose should be reduced in patients with severe hepatic impairment
- Kidney impairment – limited data are available; use with caution in patients with severe renal impairment
- Elderly patients – clearance may be reduced; consider a lower dose
Rare but potentially life-threatening skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with modafinil use. These reactions have occurred within 1–5 weeks of starting treatment. Stop taking modafinil immediately and seek emergency medical attention if you develop a widespread rash, skin blisters, peeling skin, mouth sores, or fever. Do not restart modafinil if a serious skin reaction occurs.
Pregnancy and Breastfeeding
Modafinil is not recommended during pregnancy. Animal studies have demonstrated developmental toxicity including embryolethal effects and skeletal variations. Post-marketing data from pregnancy registries have suggested a possible increased risk of congenital malformations. If you are pregnant, think you may be pregnant, or are planning to become pregnant, inform your doctor immediately. An alternative treatment approach should be considered.
It is not known whether modafinil passes into breast milk. Because of the potential for adverse effects in the nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of the medicine to the mother. Consult your doctor for guidance.
Use in Children and Adolescents
Modafinil is not approved for use in children and adolescents under 18 years of age. Clinical trials in paediatric populations were associated with serious skin reactions (including SJS) and psychiatric adverse events. The European Medicines Agency (EMA) has specifically recommended against the use of modafinil in children.
Driving and Operating Machinery
While modafinil is prescribed to improve wakefulness, it does not fully restore normal alertness in all patients. Some individuals may experience dizziness, blurred vision, or difficulty concentrating. You should assess your individual response to modafinil before driving or operating heavy machinery. Modafinil does not replace the need for adequate sleep, and patients with underlying sleep disorders should discuss driving safety with their doctor.
How Does Modafinil Interact with Other Drugs?
Modafinil is a moderate inducer of CYP3A4, which means it can reduce the blood levels and effectiveness of many medications metabolised by this enzyme. Most critically, it reduces the efficacy of hormonal contraceptives. It also inhibits CYP2C19, which can increase levels of drugs like diazepam and omeprazole. Always inform your doctor about all medications you are taking.
Modafinil has a complex drug interaction profile because it affects multiple cytochrome P450 enzymes. It is a moderate inducer of CYP3A4 (and to a lesser extent CYP1A2 and CYP2B6) and a reversible inhibitor of CYP2C19. This dual action means it can both decrease and increase the levels of other drugs depending on the metabolic pathway involved. The following tables summarise the most clinically important interactions.
Major Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Hormonal Contraceptives (ethinylestradiol, levonorgestrel) | Contraception | CYP3A4 induction reduces contraceptive blood levels by up to 50%, significantly reducing effectiveness | Use alternative or additional non-hormonal contraception during treatment and for 2 months after stopping modafinil |
| Cyclosporine | Immunosuppressant | CYP3A4 induction may significantly reduce cyclosporine blood levels, risking organ transplant rejection | Monitor cyclosporine trough levels closely; dose increase may be necessary |
| Midazolam / Triazolam | Benzodiazepines | CYP3A4 induction reduces benzodiazepine levels, potentially reducing sedative effectiveness | Monitor clinical response; dose adjustment of the benzodiazepine may be needed |
| Warfarin | Anticoagulant | Modafinil may inhibit CYP2C9, increasing warfarin levels and bleeding risk | Monitor INR more frequently when starting or stopping modafinil; adjust warfarin dose as needed |
Moderate Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Phenytoin | Antiepileptic | CYP2C19 inhibition by modafinil may increase phenytoin levels, raising toxicity risk | Monitor phenytoin levels closely; dose reduction may be needed |
| Carbamazepine / Phenobarbital | Antiepileptics / CYP3A4 inducers | These strong CYP3A4 inducers may reduce modafinil blood levels, decreasing its effectiveness | Monitor wakefulness response; modafinil dose increase may be considered |
| Diazepam | Benzodiazepine (CYP2C19 substrate) | CYP2C19 inhibition by modafinil may increase diazepam levels | Monitor for increased sedation; diazepam dose reduction may be needed |
| Omeprazole | Proton pump inhibitor (CYP2C19 substrate) | CYP2C19 inhibition may increase omeprazole exposure | Generally well tolerated; monitor for gastrointestinal side effects |
| Ketoconazole / Itraconazole | Antifungals (CYP3A4 inhibitors) | May increase modafinil blood levels by inhibiting its metabolism | Monitor for increased side effects; consider lower modafinil dose |
| SSRIs / SNRIs (e.g. fluoxetine, venlafaxine) | Antidepressants | Complex interaction; potential for increased serotonergic effects and altered antidepressant levels | Use with caution; monitor for changes in mood or adverse effects |
Modafinil significantly reduces the effectiveness of hormonal contraceptives including the combined oral contraceptive pill, progestogen-only pill, contraceptive patch, and vaginal ring. Women of childbearing potential must use an alternative or additional non-hormonal method of contraception (such as condoms, a copper IUD, or a diaphragm) throughout treatment with modafinil and for two full months after discontinuing the medication, because the enzyme-inducing effect persists.
What Is the Correct Dosage of Modafinil?
The recommended dose for adults is 200 mg once daily in the morning for narcolepsy and obstructive sleep apnea, or 200 mg approximately one hour before the start of a work shift for shift work sleep disorder. Modafinil is not approved for use in children under 18.
Always take modafinil exactly as prescribed by your doctor. Do not exceed the recommended dose. Modafinil tablets should be swallowed whole with water. For narcolepsy and obstructive sleep apnea, take the tablet in the morning. For shift work sleep disorder, take it approximately one hour before the beginning of your work shift.
Narcolepsy
Adults with Narcolepsy
Recommended dose: 200 mg once daily, taken in the morning
Dose range: 200–400 mg per day (as a single dose or split into morning and midday doses)
Some patients may benefit from a higher dose of up to 400 mg/day, although clinical trials have not consistently demonstrated additional benefit beyond 200 mg. Doses above 400 mg/day are not recommended. Your doctor will determine the optimal dose based on your response.
Obstructive Sleep Apnea (Adjunct to CPAP)
Adults with Residual Sleepiness Despite CPAP
Recommended dose: 200 mg once daily, taken in the morning
Modafinil is only for residual excessive sleepiness that persists despite optimal CPAP use. It does not replace CPAP therapy. Continue using your CPAP device as directed by your doctor.
Shift Work Sleep Disorder
Adults Working Non-Traditional Hours
Recommended dose: 200 mg taken as a single dose approximately 1 hour before the start of the work shift
Modafinil helps maintain wakefulness during the shift but does not replace the need for adequate rest. Practice good sleep hygiene on days off.
Special Populations
Elderly Patients
Clearance of modafinil may be reduced in elderly patients. A lower dose of 100 mg once daily may be appropriate, with gradual dose titration based on response and tolerability.
Patients with Severe Hepatic Impairment
The dose should be reduced by half (100 mg once daily) in patients with severe liver disease, as the clearance of modafinil is significantly reduced.
Children and Adolescents
Modafinil is not approved for use in patients under 18 years of age. Clinical trials in children were associated with serious adverse events including severe skin reactions. Do not give modafinil to children.
Missed Dose
If you miss a dose, skip it and take your next dose at the usual time. Do not take a double dose to compensate. If you miss your morning dose for narcolepsy or OSA, do not take it later in the day, as this may cause insomnia at night.
Overdose
Symptoms of modafinil overdose may include agitation, insomnia, anxiety, irritability, confusion, nervousness, tremor, palpitations, nausea, diarrhoea, and sleep disturbances. In severe cases, tachycardia, hypertension, and chest pain may occur. There is no specific antidote for modafinil overdose. Seek immediate medical attention if you suspect an overdose. Contact your local emergency services or poison control centre without delay.
What Are the Side Effects of Modafinil?
The most common side effects of modafinil are headache (affecting up to 34% of patients), nausea, nervousness, insomnia, and anxiety. While most side effects are mild to moderate and often resolve with continued use, rare but serious reactions include Stevens-Johnson syndrome, angioedema, and psychiatric symptoms.
Like all medicines, modafinil can cause side effects, although not everybody gets them. Most side effects are dose-dependent and tend to be more common at higher doses. Contact your doctor if any side effect persists, worsens, or concerns you.
- Any skin rash, blisters, peeling skin, or mouth sores (possible Stevens-Johnson syndrome or toxic epidermal necrolysis)
- Swelling of the face, eyes, lips, tongue, or throat (angioedema)
- Difficulty breathing or swallowing
- Fever with rash and organ involvement (Drug Reaction with Eosinophilia and Systemic Symptoms – DRESS syndrome)
- Suicidal thoughts, hallucinations, mania, aggression, or psychosis
- Chest pain, irregular heartbeat, or shortness of breath
Very Common
May affect more than 1 in 10 people
- Headache (the most frequently reported side effect, occurring in up to 34% of patients)
Common
May affect up to 1 in 10 people
- Nausea
- Nervousness and anxiety
- Insomnia (difficulty sleeping)
- Dizziness
- Diarrhoea
- Dry mouth
- Decreased appetite
- Upper respiratory tract infection (pharyngitis, rhinitis)
- Back pain
- Palpitations
- Dyspepsia (indigestion)
Uncommon
May affect up to 1 in 100 people
- Depression, mood changes, irritability
- Confusion, difficulty concentrating
- Tremor, paraesthesia (tingling sensations)
- Blurred vision, dry eyes
- Tachycardia (fast heart rate), hypertension
- Constipation, abdominal pain, flatulence
- Elevated liver enzymes
- Skin rash, pruritus (itching), sweating
- Muscle stiffness, joint pain
- Urinary frequency, abnormal urine
- Thirst, peripheral oedema
Rare and Very Rare
May affect up to 1 in 1,000 people or fewer
- Stevens-Johnson syndrome (SJS) – severe skin blistering and peeling
- Toxic epidermal necrolysis (TEN) – widespread skin detachment
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
- Angioedema – severe swelling of face, lips, tongue, or throat
- Multi-organ hypersensitivity reactions
- Psychosis, hallucinations, mania
- Suicidal ideation
- Agranulocytosis (severe reduction in white blood cells)
If you experience any side effects not listed here, or if any side effect becomes severe, contact your doctor or pharmacist. Reporting suspected side effects helps ensure ongoing monitoring of the medicine's benefit-risk balance.
How Should You Store Modafinil?
Store modafinil tablets at room temperature (20–25°C / 68–77°F), away from moisture and light. Keep out of the reach and sight of children. As a controlled substance, store securely to prevent misuse or diversion.
Keep modafinil in its original packaging to protect it from moisture and light. Store at controlled room temperature. Brief excursions to 15–30°C (59–86°F) are permitted. Do not store in the bathroom or near a sink, as humidity can degrade the tablets.
Because modafinil is a Schedule IV controlled substance, it should be stored securely and not shared with others. Misuse of modafinil is illegal and can be dangerous. Keep track of your tablets and report any missing medication to your doctor or pharmacist.
Check the expiry date (marked "EXP" on the carton and blister) before taking any tablets. The expiry date refers to the last day of the stated month. Do not flush unused tablets down the toilet or throw them in household waste. Return any unused or expired medication to your pharmacy for safe disposal.
What Does Modafinil Contain?
Each modafinil tablet contains the active ingredient modafinil (100 mg or 200 mg) and several inactive ingredients necessary for tablet manufacture. The tablets are white to off-white, round (100 mg) or capsule-shaped (200 mg).
Active Ingredient
The active substance is modafinil, a racemic compound consisting of equal amounts of R-modafinil (armodafinil) and S-modafinil. Each 100 mg tablet contains 100 mg of modafinil. Each 200 mg tablet contains 200 mg of modafinil.
Inactive Ingredients (Excipients)
The other ingredients typically include: lactose monohydrate, microcrystalline cellulose, pregelatinised starch, croscarmellose sodium, povidone, and magnesium stearate. These are standard pharmaceutical excipients used to ensure proper tablet formation, disintegration, and absorption. Patients with lactose intolerance should note the presence of lactose monohydrate.
Tablet Appearance and Packaging
100 mg tablets: White to off-white, round, scored on one side (allowing the tablet to be split in half if needed).
200 mg tablets: White to off-white, capsule-shaped (oblong), scored on one side.
Available in blister packs or bottles of 30, 60, 90, and 100 tablets. Not all pack sizes may be marketed in your country.
How Does Modafinil Work in the Body?
Modafinil promotes wakefulness through multiple mechanisms, primarily by inhibiting the dopamine transporter (DAT) to increase extracellular dopamine, and by activating orexin/hypocretin neurons in the hypothalamus. Its elimination half-life of 12–15 hours allows once-daily dosing. It is metabolised mainly by CYP3A4 in the liver.
The precise mechanism of action of modafinil is not fully understood, but research has identified several key pathways through which it promotes wakefulness. Unlike amphetamines, which cause a broad release of catecholamines (dopamine, norepinephrine, and serotonin), modafinil acts more selectively and does not produce the same degree of peripheral sympathetic stimulation or euphoria.
Primary Mechanisms
Dopamine reuptake inhibition: Modafinil binds to the dopamine transporter (DAT), inhibiting the reuptake of dopamine into presynaptic neurons. This increases extracellular dopamine concentrations in key brain regions involved in wakefulness, including the nucleus accumbens and prefrontal cortex. Studies using DAT-knockout mice have confirmed that this mechanism is essential for modafinil's wake-promoting effects.
Orexin/Hypocretin activation: Modafinil activates orexin (hypocretin) neurons in the lateral hypothalamus, which play a central role in maintaining wakefulness and stabilising the sleep-wake transition. This is particularly relevant in narcolepsy, where orexin neurons are depleted. However, modafinil can still promote wakefulness in orexin-deficient animals, indicating that this is not its sole mechanism.
Additional neuromodulatory effects: Modafinil also increases histamine release in the tuberomammillary nucleus, enhances norepinephrine signalling in the locus coeruleus, and modulates GABA and glutamate neurotransmission. These secondary effects contribute to its overall wakefulness-promoting and cognitive-enhancing properties.
Pharmacokinetic Profile
After oral administration, modafinil is readily absorbed from the gastrointestinal tract. Peak plasma concentrations are reached approximately 2–4 hours after dosing. The bioavailability is approximately 80%, and absorption may be slightly delayed (but not reduced) by food. Modafinil is approximately 60% bound to plasma proteins, primarily to albumin.
Modafinil is extensively metabolised in the liver, primarily by the CYP3A4 enzyme (with some contribution from CYP2C19), to two major inactive metabolites: modafinil acid and modafinil sulfone. Approximately 80% of the administered dose is excreted in the urine (less than 10% as unchanged drug) and a small portion in the faeces.
The elimination half-life is 12–15 hours, which supports once-daily dosing. Steady-state concentrations are reached within 2–4 days of repeated dosing. The R-enantiomer (armodafinil) has a longer half-life than the S-enantiomer, contributing to sustained wakefulness throughout the day. Importantly, modafinil is a moderate inducer of CYP3A4, which is responsible for its clinically significant interactions with hormonal contraceptives and other CYP3A4 substrates.
Frequently Asked Questions About Modafinil
Modafinil is a prescription wakefulness-promoting agent used to treat excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea (as an adjunct to CPAP therapy), and shift work sleep disorder. It does not cure these conditions but helps patients stay awake during waking hours. It is not approved for use as a general cognitive enhancer or study aid, and using it without a prescription is both illegal and potentially dangerous.
Long-term studies of up to 40 weeks have shown that modafinil maintains its wakefulness-promoting effects without significant tolerance development. The side effect profile remains consistent over time, with headache and nausea being the most common complaints. However, modafinil is a Schedule IV controlled substance due to its potential for dependence, and long-term use should be regularly reviewed by your doctor to ensure continued benefit and medical appropriateness.
Modafinil has a lower abuse potential compared to traditional stimulants such as amphetamines and methylphenidate, which is why it is classified as a Schedule IV rather than Schedule II controlled substance. It produces less euphoria and has a different neurochemical profile. However, it does act on dopamine pathways, and cases of psychological dependence have been reported, particularly at higher-than-prescribed doses. Always take modafinil exactly as prescribed by your doctor and do not share it with others.
While both modafinil and caffeine promote wakefulness, they work through fundamentally different mechanisms. Modafinil primarily acts on dopamine and orexin pathways, while caffeine blocks adenosine receptors. Modafinil provides more sustained wakefulness (12–15 hour half-life compared to 5–6 hours for caffeine) with generally less jitteriness, anxiety, and cardiovascular stimulation. However, modafinil is a prescription medication indicated only for specific diagnosed sleep disorders, whereas caffeine is freely available and not a controlled substance.
Yes, this is one of the most important drug interactions with modafinil. As a moderate inducer of the CYP3A4 enzyme, modafinil can reduce the blood levels and effectiveness of hormonal contraceptives by up to 50%. This includes the combined oral contraceptive pill, progestogen-only pill, contraceptive patch, and vaginal ring. Women taking modafinil must use an alternative or additional non-hormonal method of contraception (such as condoms, a copper IUD, or a diaphragm) throughout treatment and for two full months after stopping modafinil.
Modafinil is prescribed specifically to help patients with excessive sleepiness stay more alert, and clinical studies suggest it can improve driving performance in patients with narcolepsy or shift work sleep disorder. However, it does not fully restore normal wakefulness in all patients and does not replace adequate sleep. Some individuals may experience dizziness or blurred vision. You should carefully assess your individual response to modafinil before driving and follow your doctor's specific advice regarding driving safety and fitness to drive.
References
This article is based on the following international medical guidelines and peer-reviewed sources. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews of randomised controlled trials.
- Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. Journal of Clinical Psychiatry. 2006;67(4):554–566. doi:10.4088/JCP.v67n0406
- Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33(7):1477–1502. doi:10.1038/sj.npp.1301534
- European Medicines Agency (EMA). Modafinil – Article 31 referral – Assessment Report. EMA/771571/2011. November 2011.
- U.S. Food and Drug Administration (FDA). Provigil (modafinil) – Prescribing Information. Revised 2023. Reference ID: 4940956.
- Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705–1711. doi:10.1093/sleep/30.12.1705
- Billiard M, Bassetti C, Dauvilliers Y, et al. EFNS guidelines on management of narcolepsy. European Journal of Neurology. 2006;13(10):1035–1048. doi:10.1111/j.1468-1331.2006.01473.x
- Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301(11):1148–1154. doi:10.1001/jama.2009.351
- British National Formulary (BNF). Modafinil. NICE BNF monograph. Accessed February 2026.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in neurology, sleep medicine, and clinical pharmacology.
Medical Writers
Board-certified physicians specialising in neurology, sleep medicine, and clinical pharmacology with documented academic and clinical experience.
Medical Reviewers
Independent review board ensuring clinical accuracy, adherence to international guidelines (AASM, EMA, FDA, WHO), and evidence level 1A standards.
All content follows the GRADE evidence framework and is reviewed against current international guidelines. We have no commercial funding or pharmaceutical sponsorship. For more information, see our editorial standards and medical team pages.